Successful treatment with PR-mini-CHP for elderly relapsed and refractory mantle cell lymphoma

Abstract Mantle cell lymphoma (MCL) often shows repeated remission, relapse, and resistance to therapy, and the current standard treatment for aggressive MCL, particularly in elderly patients remains inadequate. Ibrutinib has achieved good response rates; however, primary and secondary resistance has been reported with poor clinical outcomes. Furthermore, a high-risk subset characterized by TP53 aberrations, high Ki67% levels, a blastoid histology, and complex karyotype obtained limited benefits. Polatuzumab vedotin (Pola) has potential for the treatment of relapsed/refractory (R/R) B-cell lymphoma. We herein showed that Pola-R-mini-CHP was an effective and safe therapy for elderly R/R MCL patients with high-risk markers.